国泰海通证券研究·2025-09-16 12:02Core Viewpoint - The recent Shanghai Leading Industry Conference and the 14th Pharmaceutical CEO Forum, along with the 5th Artificial Intelligence Conference, successfully highlighted the forefront trends and cross-industry opportunities in the biopharmaceutical and technology sectors [2][8]. Group 1: Conference Overview - The conference gathered nearly 100 industry leaders, representatives from around 200 listed companies, and close to 1,000 investors, creating a platform for deep industry insights and investment value [2]. - Chen Zhongyi, Vice President of Guotai Junan, emphasized the company's role as a "witness and companion" in the leading industry since the first Pharmaceutical CEO Forum in 2012, which has evolved alongside China's innovative drug industry [4]. Group 2: Key Themes and Discussions - The biopharmaceutical sessions focused on three main themes: innovative drug development, medical technology innovation, and global layout, featuring nearly 10 roundtable discussions with executives from about 50 leading pharmaceutical companies [5]. - The technology sessions concentrated on the disruptive impact of AI on industries, discussing breakthroughs in large-scale AI chips, intelligent computing centers, and high-performance switches, as well as innovative applications in gaming, video content generation, and health management [5]. Group 3: Future Directions - The conference is recognized as a significant platform for understanding trends in biopharmaceuticals and technology, aiming to further promote the integration of these sectors [8]. - Guotai Junan Research Institute plans to leverage its professional strengths and company resources to contribute to the high-quality development of leading industries [8].